Preeti Chaudhary, MD
Hematology & Oncology · Pomona, CANPI 1255597456
Payments from drug & device makers
Across 119 payments — averaging $133.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Autolus Inc$5K
- AstraZeneca$5K
- Novartis$3K
- Pfizer$254
- Seagen Inc.$223
- Gilead$208
- plus $1K from 26 others
What the payments were for
- Consulting fees$6,34040%
- Speaking & faculty fees$5,13032%
- Food & beverage$2,16714%
- Education$6634%
- Other$1,54810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Autolus Inc | 4 | $5,391 |
| AstraZeneca(2 entities) | 14 | $5,045 |
| Novartis | 29 | $3,374 |
| Pfizer | 11 | $254 |
| Seagen Inc. | 3 | $223 |
| Gilead(2 entities) | 6 | $208 |
| Incyte Corporation | 2 | $193 |
| E.r. Squibb & Sons, L.L.C. | 9 | $172 |
| GSK | 7 | $161 |
| Johnson & Johnson(2 entities) | 6 | $153 |
| Sanofi | 3 | $61 |
| Amgen | 2 | $47 |
| Bayer | 2 | $47 |
| Bristol Myers Squibb | 2 | $45 |
| Beone Medicines USA, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| AVEO Pharmaceuticals, Inc. | 1 | $34 |
| AbbVie | 1 | $33 |
| Springworks Therapeutics, Inc. | 1 | $32 |
| Sobi, Inc | 1 | $31 |
| Mirati Therapeutics, Inc. | 1 | $30 |
| Beigene USA, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Array Biopharma Inc | 1 | $24 |
| EMD Serono, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$2,345
How this compares
$15,847 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 43 | $888,480 |
| XtandiEnzalutamide | 52 | $661,141 |
| ZejulaNiraparib Tosylate | 14 | $302,990 |
| PomalystPomalidomide | 13 | $278,100 |
| RetevmoSelpercatinib | 24 | $215,581 |
| JakafiRuxolitinib Phosphate | 11 | $188,718 |
| SprycelDasatinib | 11 | $184,256 |
| KisqaliRibociclib Succinate | 14 | $179,964 |
| VenclextaVenetoclax | 12 | $174,865 |
| EliquisApixaban | 118 | $64,663 |
| XareltoRivaroxaban | 30 | $28,052 |
| Letrozole | 178 | $5,484 |
| Hydroxyurea | 67 | $1,876 |
| Exemestane | 12 | $1,727 |
| Tamoxifen Citrate | 39 | $1,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $45 | $888,48043 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $172 | $462,35624 claims |
| GSKZejula | $161 | $302,99014 claims |
| Lilly USA, LLCRetevmo | $20 | $215,58124 claims |
| Incyte CorporationJakafi | $193 | $188,71811 claims |
| NovartisKisqali | $3,374 | $179,96414 claims |
| AbbVieVenclexta | $33 | $174,86512 claims |
| PfizerEliquis | $254 | $64,663118 claims |
| Johnson & JohnsonXarelto | $153 | $28,05230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Pomona
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.